Norman W. Barton MD, PhD

Dr. Barton has been with Shire R&D since 2008. Norman earned a PhD and MD at Penn State. He trained in neurology at Cornell University, The New York Hospital. Norman’s biomedical research career spans over 30 years with leadership responsibility for clinical development programs in both the academic and biotech sectors. The unifying principle throughout has been the development of effective first-in-class therapeutics for rare disorders and underserved populations such as Gaucher, Fabry and Niemann-Pick Disease, Metachromatic Leukodystrophy, Duchenne Muscular Dystrophy and retinopathy of prematurity and bronchopulmonary dysplasia in premature infants. Serving in the capacity of Chief, Clinical Investigations and Therapeutics Section at the National Institute of Neurological Disorders and Stroke, Dr. Barton conceived and executed the clinical development program that lead to the approval of Ceredase as the first safe and effective enzyme replacement product for Gaucher Disease. Recognition for this contribution included the Meritorious Service Medal from the Public Health Service, the Outstanding Achievement Award from the National Gaucher Foundation and the Distinguished Alumnus Award from Pennsylvania State University.